Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.08 USD | -1.10% | -20.67% | +38.68% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Financials (USD)
Sales 2024 * | 68.81M | Sales 2025 * | 73.31M | Capitalization | 280M |
---|---|---|---|---|---|
Net income 2024 * | -110M | Net income 2025 * | -116M | EV / Sales 2024 * | 4.07 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.82 x |
P/E ratio 2024 * |
-2.54
x | P/E ratio 2025 * |
-2.68
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.9% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | -5.50% | ||
1 week | -21.01% | ||
Current month | -24.23% | ||
1 month | -2.07% | ||
3 months | +13.86% | ||
6 months | +37.10% | ||
Current year | +40.60% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 13.05 | -1.36% | 89 574 |
24-04-18 | 13.23 | -5.50% | 154,132 |
24-04-17 | 14 | -8.85% | 190,836 |
24-04-16 | 15.36 | -4.89% | 211,027 |
24-04-15 | 16.15 | -1.82% | 161,287 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.60% | 280M | |
-1.82% | 41.35B | |
+44.25% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- ENTA Stock